These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15314519)

  • 1. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
    Posadas EM; Davidson B; Kohn EC
    Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics as a guiding tool for more effective personalized therapy.
    Lee JM; Kohn EC
    Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii205-10. PubMed ID: 20943616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HE4 in ovarian cancer: from discovery to clinical application.
    Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
    Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
    Tchabo NE; Liel MS; Kohn EC
    Am J Pharmacogenomics; 2005; 5(3):141-8. PubMed ID: 15952868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
    Boyce EA; Kohn EC
    Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of proteomics in ovarian cancer prevention and treatment.
    Meani F; Pecorelli S; Liotta L; Petricoin EF
    Mol Diagn Ther; 2009; 13(5):297-311. PubMed ID: 19791834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma proteomic pattern as biomarkers for ovarian cancer.
    Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
    Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic profiling in ovarian cancer.
    Kim G; Minig L; Kohn EC
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
    Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
    Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
    Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
    J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic biomarkers in epithelial ovarian cancer.
    Gloss BS; Samimi G
    Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
    Ryu J; Thomas SN
    Molecules; 2021 May; 26(9):. PubMed ID: 34063568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
    Lalwani N; Prasad SR; Vikram R; Shanbhogue AK; Huettner PC; Fasih N
    Radiographics; 2011; 31(3):625-46. PubMed ID: 21571648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer in the proteomics era.
    Annunziata CM; Azad N; Dhamoon AS; Whiteley G; Kohn EC
    Int J Gynecol Cancer; 2008; 18 Suppl 1():1-6. PubMed ID: 18336391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epithelial ovarian cancer - a change of paradigm].
    Heinzelmann-Schwarz V
    Ther Umsch; 2011 Oct; 68(10):565-72. PubMed ID: 21968896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions in the management of epithelial ovarian cancer.
    Blagden S; Gabra H
    Future Oncol; 2008 Jun; 4(3):403-11. PubMed ID: 18518765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontline treatment of epithelial ovarian cancer.
    Goh J; Mohan GR; Ladwa R; Ananda S; Cohen PA; Baron-Hay S
    Asia Pac J Clin Oncol; 2015 Dec; 11 Suppl 6():1-16. PubMed ID: 26669253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
    Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
    Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.